Roche builds evidence for Evrysdi’s benefits in younger SMA patientsRoche has highlighted new data with its oral treatment for spinal muscular atrophy (SMA) – Evrysdi – showing Share XRoche builds evidence for Evrysdi’s benefits in younger SMA patientshttps://pharmaphorum.com/news/roche-builds-evidence-for-evrysdis-benefits-younger-sma-patients/
NICE ‘no’ to Roche’s risdiplam for SMA not unexpected, says patient groupNICE has rejected routine NHS funding for Roche’s Evrysdi (risdiplam) for spinal muscular atrophy drug in draft guidance, Share XNICE ‘no’ to Roche’s risdiplam for SMA not unexpected, says patient grouphttps://pharmaphorum.com/news/nice-no-to-roches-risdiplam-for-sma-not-unexpected-says-patient-group/
Evrysdi has ‘real world impact’ on lives of babies with severe SMA, says RocheRoche’s Genentech unit has released further data from a key trial of Evrysdi, its oral treatment for spinal Share XEvrysdi has ‘real world impact’ on lives of babies with severe SMA, says Rochehttps://pharmaphorum.com/news/evrysdi-has-real-world-impact-on-lives-of-babies-with-severe-sma-says-roche/
